GENEVA, July 9 -- JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. filed a patent application (CN2026/070744) for “USE OF GLP-1 RECEPTOR AGONIST IN TREATMENT OF DIABETES”. With publication no. WO/2026/145807, here are the other details related to the patent application:
Kind: Initial Publication with ISR [A1]
IPC: A61K 31/454
Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).
Disclaimer: Curated by HT Syndication....